Skip to main content

Table 3 Functional and familial burden for psychosis

From: Evaluation of outcomes for psychosis and epilepsy treatment delivered by primary health care workers in Nepal: a cohort study

  Program (n = 48) Control (n = 17) ANCOVA Full cohort T
Mean (SD) Mean (SD) Effect size
F, partial eta2
P-val* Mean (SD) Effect Size
Z, r
P-val**
WHODAS 0.52, 0.01 0.52    4.60, 0.57 < 0.0001
Baseline 46.1 (24.2) 37.4 (25.6)    43.8 (24.7)   
end point 23.1 (20.8) 27.1 (30.9)    24.1 (23.7)   
Δ score − 23.0 (27.0) − 10.3 (44.3)    − 19.7 (32.6)   
BAS      0.29, < 0.01 0.59    6.81, 0.84 < 0.0001
Baseline 76.5 (8.0) 76.0 (8.2)    76.4 (8.0)   
end point 63.3 (6.5) 62.1 (9.3)    62.9 (7.3)   
Δ score − 13.3 (8.6) − 13.9 (11.5)    − 13.4 (9.4)   
FIS: symptoms and social behavior   0.16, < 0.01 0.69    5.94, 0.74 < 0.0001
Baseline 46.5 (9.7) 41.2 (11.4)    45.1 (10.4)   
end point 31.1 (9.4) 31.6 (11.0)    31.2 (9.8)   
Δ Score − 15.4 (12.3) − 9.6 (15.8)    − 13.9 (13.4)   
FIS: impact on caregiver    2.02, 0.03 0.16    5.13, 0.64 < 0.0001
Baseline 12.0 (5.9) 10.9 (6.3)    11.7 (6.0)   
end point 5.9 (4.3) 7.6 (5.7)    6.3 (4.7)   
Δ score − 6.1 (6.4) − 3.3 (7.9)    − 5.4 (6.9)   
  1. WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule, FIS Family Interview Schedule
  2. * P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
  3. ** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)